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Background/aim: Prediction of response to chemotherapy and prognosis bears clinical significance in patients with lung cancer. The
aim of the study was to examine the association between apelin expression in tumor tissues and overall survival, progression-free
survival, chemoresistance, and treatment response in stage 4 nonsmall cell lung cancer (NSCLC) patients undergoing chemotherapy.
Materials and methods: A total of 81 patients who received chemotherapy due to a biopsy-documented diagnosis of NSCLC between
2004 and 2011 were retrospectively studied. Bronchoscopic biopsy samples were examined immunohistochemically.
Results: Of the overall study population (n = 81), the mean age was 59.0 ± 9.2 years; 83% (n = 67) were male and 17% (n = 14) were
female. All patients received chemotherapy. A total of 30 patients (37%) had no apelin positivity, while 21 (30%) had 1 +, 20 (25%) had
2 +, and 10 (12%) had 3 + apelin positivity. We detected no association between apelin positivity and overall survival, 6-month survival,
or 1-year survival rates (P = 0.05, 0.74, and 0.63). Patients with apelin expression as compared to those without it had shorter overall
survival (P = 0.05).
Conclusion: Our results suggest that apelin, an angiogenic factor, does not seem to provide significant prognostic information in this
patient group.
Key words: Nonsmall cell lung cancer, apelin, prognosis

1. Introduction
Lung cancer has become the leading malignancy afflicting
human beings since 1985, in most part due to the global
increase in smoking rates (1), and is responsible for 12.8%
of all cancer cases. It is responsible for most cancer deaths,
i.e. 17.8%, worldwide (2). For all lung cancer patients,
only 15% live more than 5 years after diagnosis. Lung
cancer incidence decreases in women corresponding to an
increase in men (3).
The most important factor in the etiology of lung cancer
is smoking. Smoking is responsible for approximately
85%–90% of lung cancer (4). Smoking increases the risk
of lung cancer by 30 times compared to nonsmokers (5).
Passive smoking increases the risk by about two times
(6). Another important factor that played a role in the
development of lung cancer in Turkey is asbestos exposure.
Smokers being in contact with asbestos increases the risk
of lung cancer by 90 times (7).
* Correspondence: sinemozsari@yahoo.com

Nonsmall cell lung cancer (NSCLC) represents
approximately 85% of all lung cancers (8). At presentation,
85% of patients have stage 3 or 4 disease, rendering
chemotherapy the first line of treatment option. However,
cure is not possible with chemotherapy in stage 4 disease
(9). Studies focusing on adjuvant chemotherapy since
1995 have only provided a very limited 5-year survival
advantage in the order of 5% (2). Due to the presence of
significant interpatient variability in terms of response
rates to chemotherapy, prognostic predictors for specific
chemotherapy regimens are of clinical importance. This
will not only allow avoiding unnecessary toxicity from
chemotherapy, but will also facilitate customized treatment
for each patient. Thus, in recent years there has been a
dramatic increase in the number of studies examining the
role of molecular markers in the prediction of prognosis
and response to treatment in patients with lung cancer.
In earlier studies, it was shown that high ERCC1 levels in
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NSCLC patients are an independent prognostic predictor
rather than low ERCC1 levels (10). The presence of K-ras
mutation has poor prognostic significance for survival in
patients (11).
Apelin is a peptide secreted from the cell surface of
various tissues including lungs, heart, kidneys, adipose
tissue, and breast tissue that functions as a ligand for G
proteins. The apelin receptor was originally described
by O’Dowd et al. (12) and consists of a 77-amino acid
prepropeptide. Proteases are responsible for the formation
of apelin-13, apelin-17, and apelin-36 through cleavage
from the C-terminal. Among these isoforms with different
activities, the shortest isoform is the most potent activator of
the apelin receptor (APJ), and it is found in the endothelial
cells responsible for the embryogenic development of the
vascular system. Apelin and its receptor can be detected
in high concentrations in the endothelial cells of the
vascular wall in adults (13). Apelin also plays different
roles in a number of physiological processes such as fluid
hemostasis, regulation of food intake, cell proliferation,
glucose utilization, and angiogenesis. In humans and mice,
apelin has been found to be produced by adipocytes, which
is an indication of the fact that apelin is an adipokine (14).
Currently, apelin is considered to be an angiogenic
factor similar to VEGF, and its potential role in limiting
tumor angiogenesis is being studied. One third of human
cancers produce apelin, which stimulates tumor growth
(15). In experimental studies with mice, increased
APJ mRNA has been detected, with APJ expression in
all peripheral tissues. Higher detection rates in lung
and heart tissues have also been found (16). The site
of tissue apelin expression is determined by vascular
endothelial cells, adipose tissue, and epithelial cells. In

mouse embryos, APJ expression has been detected in
endothelial cells of the newly developing blood vessels
(17). The apelin/APJ system triggers vascular endothelial
cell proliferation through the induction of cell-to-cell
interactions. Currently, there is a search for agents that
are able to inhibit tumor angiogenesis, and in this regard
regulation of APJ activity may allow the development of
molecules that can normalize vascular growth patterns.
Such agents may increase the therapeutic efficacy through
the vessel dilating effects of antiangiogenic drugs. APJ and
apelin immunohistochemical images are shown in human
umbilical vena endothelial cells in Figure 1 (18).
The primary objective of this study was to examine the
association between apelin expression in tumor tissues
overall, as well as progression-free survival, and to compare
response rates for the assessment of chemoresistance
in stage 4 NSCLC patients undergoing chemotherapy.
Secondary endpoints included the assessment of the
association between apelin positivity and side effects of
chemotherapy.
2. Materials and methods
2.1. Study population and protocol
We examined patients who received chemotherapy in
the Department of Pulmonary Medicine due to a biopsydocumented diagnosis of NSCLC between 2004 and
2011 retrospectively. Patients were included in the study
if adequate information on disease stage, response to
chemotherapy, side effects, and prognosis was present in
patient files. In the case of lacking data on overall sideeffect profile, hematological side effects were recorded, if
present.

Figure 1. Immunohistochemical images of APJ and apelin in human umbilical vena endothelial cells, from Kleinz and
Davenport (18).
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A total of 81 NSCLC patients with adequate amounts of
tissue sample for an immunohistochemical examination of
apelin were included. All patients underwent transnasal or
transoral fiberoptic bronchoscopy (Olympus CLE-10) after
local anesthesia with topical lidocaine HCl 2% (max. 10
mL). Diagnosis was based on biopsy results in all patients
and biopsy samples were assessed histopathologically
before treatment. The total number of chemotherapy
courses, chemotherapeutic agents administered, response
to chemotherapy during follow-up, and hematological side
effects of chemotherapy were recorded and prognosis was
evaluated. Overall survival was defined as the time from
diagnosis to death, and progression-free survival was
defined as the time from the start of chemotherapy to the
first day of progression. Survival analyses were based on
the last day of the study follow-up period. We used CTCAE
(Common Terminology Criteria for Adverse Effects) for
the assessment of side effects occurring during the course
of chemotherapy. The study protocol was approved by our
institutional ethics committee.
2.2. Immunohistochemical examinations
Cross-sections of 5 µm in thickness, obtained from
paraffin blocks containing adequate amounts of
tumor tissue, were placed on electrostatically charged
microscope slides and were dried at 60 °C for at least 2 h.
All immunohistochemical staining procedures, including
deparaffinization and antigen exposure, were performed
in a fully automatic immunohistochemical staining
device (BenchMark XT). The primary antibody, i.e. Anti-

Apelin-12, was administered manually by instillation and
incubated for 32 min at 37 °C.
Staining in the bronchial covering epithelium and
glandular epithelial tissue was used as a positive control.
Cross-sections where the primary antibody could not
be instilled were taken as negative controls. Apelin
immunoreactivity was graded using the method proposed
by Berta et al. (18), whereby the proportion of cells with
cytoplasmic positivity was taken into account. Accordingly,
0 staining, 1 + staining, 2 + staining, or 3 + staining (as
shown in Figure 2) categories were defined on the basis of
no staining, 1% to 10% staining, 11% to 50% staining, and
greater than 50% staining, respectively.
2.3. Assessment of the response
We assessed the response to treatment by CT or PET-CT
after the 2nd, 3rd, 4th, or 6th chemotherapy courses at the
discretion of the treating physician. Treatment response
was assessed using the RECIST 1.1 criteria (Response
Evaluation Criteria in Solid Tumors).
2.4. Statistical analyses
The study data were analyzed using SPSS 20.0 for
Windows. Clinical and pathological characteristics were
compared using the Fisher exact test and chi-square test.
Overall survival and disease-free survival were evaluated
using Kaplan–Meier and log rank (Mantel–Cox) methods.
The comparison for mean age and time to progression
was performed using the t-test. P < 0.05 was considered
significant.

Figure 2. Apelin score of 3 (Anti-Apelin, 100×).
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3. Results
The mean age of the study participants was 59 ± 9.2 years.
Of the study subjects, 83% (n = 67) were male and 17% (n =
14) were female. A total of 68 patients (84%) had a history
of cigarette smoking, with an average smoking history
of 51.0 ± 30.0 pack-years. Basic clinical and pathological
characteristics of patients are shown in Table 1. Fortytwo patients (52%) had at least one concomitant medical
condition, the most frequent of which were as follows:
hypertension (12 patients, 15%), chronic obstructive
pulmonary disease (9 patients, 11%), diabetes mellitus (10
patients, 12%), and coronary artery disease (8 patients,
10%). Only 7% (6 patients) had a family history of cancer.
Diagnostic subcategories included squamous cell
carcinoma in 30 patients (37%), adenocarcinoma in 20
patients (25%), and undefined NSCLC in 31 patients
(38%). All patients had stage 4 NSCLC. The most frequent
site of distant metastasis was the lungs in 24 patients
(30%), followed by bone in 22 patients (27%) and the brain
in 15 patients (19%). Multiple metastases were present
in 31 patients (38%). While progression was observed
only in the lungs in 49 patients (61%), progression was
observed at the site of metastasis in 11 patients (14%), and
12 patients (15%) had progression both in the lungs and
at the site of metastasis. In 8 cases (10%) the patient died
before an assessment of response; thus, the progression
date was taken as the day of death. All patients received
chemotherapy, while in 51 patients (53%) radiotherapy was
administered at any one point during their follow-up for a
number of indications including metastasis, atelectasis, or
superior vena cava syndrome.
In
first-line
chemotherapy,
platinum-based
chemotherapy was administered to all patients. The most
Table 1. Basic clinical and pathological characteristics of patients.
Characteristics

Number (%)

Mean age (years)

59.0 ± 9.2

Sex (male/female)

67 (83%) / 14 (17%)

Smoking history (pack-years)

51.0 ± 30.0

Histology
NSCLC

31 (38%)

Squamous cell

30 (37%)

Adenocarcinoma

20 (25%)

Performance status (ECOG)
0

20 (25%)

1

47 (59%)

2

12 (15%)

3

1 (1%)
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preferred first-line chemotherapeutic regimen was a
cisplatin/carboplatin + gemcitabine combination (39 cases,
48%). For second-line chemotherapy, the most preferred
chemotherapeutic regimen was single-agent Taxotere.
Subgroups were identified by the positivity of apelin.
The subgroups were similar in terms of chemotherapy
regimens. All patients took antiangiogenic agents and all
patients were given tyrosine kinase inhibitors.
Chemotherapy was postponed in 40 patients (49%) due
to severe side effects, while in 11 (14%) dose reduction was
required. RBC transfusions were given to 18 patients (22%)
before or after chemotherapy, and 1 patient (1%) received a
platelet transfusion. The time to progression after first-line
chemotherapy was 26.0 ± 16.2 weeks on average. Secondline chemotherapy was given to 44 patients (54%) due to
the absence of response to first-line treatment or due to the
development of progression during follow-up. Further, 5
patients received third-line chemotherapy.
The mean overall survival was 56.3 ± 4.4 weeks. While
81% of patients (n = 66) survived for at least 6 months,
1-year survival was observed in 43% (35 patients).
Thirty patients (37%) were apelin-negative, while 21
(30%), 20 (25%), and 10 (12%) cases had 1 +, 2 +, or 3
+ apelin positivity, respectively. Although a marginally
significant association between apelin positivity and
overall survival was observed, no significant link between
apelin positivity and 6-month or 1-year survival could
be detected (P = 0.05, 0.74, and 0.63, respectively). There
were also no significant differences between chemotherapy
regimens in terms of side effects. Overall survival was
shorter in apelin-positive subjects as compared to those
without apelin positivity (P = 0.05) (as shown in Table 2
and Figure 3). Most patients without apelin positivity had
an ECOG performance status of 0–1 (P = 0.05).
A comparison between patients with different levels
of apelin positivity revealed no difference in demographic
characteristics as well as in 6-month and 1-year survival
rates (P = 0.74 and 0.63, respectively), in chemotherapy
regimens administered, and in side effects observed. When
apelin 0, 1 +, 2 +, and 3 + patients were categorized into
2 subgroups as reported previously, again no significant
differences were found. There were no significant
differences between different chemotherapy regimens in
terms of side effect profiles. We observed grade II or III
hematological toxicities in the overall patient group, and
the severity of hematological toxicities did not correlate
with apelin positivity.
4. Discussion
Most lung cancer patients already have late-stage disease
at the time of diagnosis, rendering chemotherapy the
only therapeutic option in the great majority of these
subjects. The decision to administer chemotherapy is
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Table 2. Comparison of apelin positivity with response and survival.
Characteristics

Apelin = 0
(n = 30)

Apelin ≥ 1 (+)
(n = 51)

P-value

Overall survival (weeks)

53.0 ± 8.3

44.0 ± 5.0

0.05

Partial response

10 patients (33%)

14 patients (28%)

0.60

Stable response + progression

20 patients (67%)

37 patients (73%)

0.60

Time to progression (weeks)

27.3 ± 15.1

25.2 ± 17.0

0.60

6-month survival

25 patients (83%)

41 patients (80%)

0.74

1-year survival

14 patients (47%)

21 patients (41%)

0.63

Survival (week)
Figure 3. Overall survival curves according to apelin positivity.

based on the performance status and potential side effects.
Therefore, prediction of subjects with a greater likelihood
of response to chemotherapy using prognostic parameters
or determining the subgroup of patients with a higher risk
of side effects is of great clinical significance.
In this study assessing the prognostic significance of
apelin expression by tumor tissues in advanced-stage
NSCLC patients, a marginally significant association
between apelin positivity and overall survival was

detected, while no such associations could be established
for 6-month or 1-year survival rates. Similarly, apelin
expression was not associated with differential treatment
response rates, different chemotherapy regimens, or
hematological side effects.
Our literature search has revealed only a single
study examining apelin expression in NSCLC patients
(19), where a total of 94 NSCLC patients who received
treatment between January 1997 and December 2001
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were studied. The mean age of participants was 63 years
and the female-to-male ratio was 26:68. All patients were
staged on the basis of surgical and pathological findings.
Of these patients, 35, 54, and 5 had squamous cell cancer,
adenocarcinoma, and large cell cancer, respectively. All
patients were evaluated by two independent pathology
specialists, and the staining was graded as 0, 1 +, 2 +, or 3 +
based on a staining of 0 cells, 1%–10% staining, 11%–50%
staining, or greater than 50% staining, respectively.
In the study by Berta et al., 6 different mRNAs were
detected for the apelin protein using polymerase chain
reaction analysis. Molecular analysis of the tumor and
normal lung tissues showed a significantly higher level
of apelin mRNA expression within the tumor tissues as
compared to normal lung tissues. A significant correlation
between mRNA levels and apelin positivity was also
observed as detected by immunohistochemical studies
(19). Again in the same study, H358 and H1975 cells with
endogenously low apelin expression were exposed to an
apelin-expressing vector in order to evaluate the effect of
apelin on the development of NSCLC, and a significant
increase in the expression of apelin by these cells was
detected. The apelin-expressing vector was exposed to
CD31 antibody in vivo in order to explore the effects of
apelin on angiogenesis, and a significant increase in the
microvascular density and dimensions of these cells was
observed following exposure (19). For the purpose of
survival analyses, two groups with different apelin activity,
i.e. low apelin expression with 0 or 1 + expression and high
apelin expression with 2 + or 3 + expression, were defined.
The 5-year survival rate in the low apelin expression
group was 63.3%, as compared to 29.9% in the high
apelin expression group. Multivariate analysis suggested
a prognostic role for apelin expression and lymph node
status in NSCLC. These authors concluded that apelin is
an angiogenic factor and may represent an independent
prognostic parameter associated with poor prognosis that
may assist in treatment decisions.

Our study involved only immunohistochemical
assessments and a single pathologist evaluated the biopsy
material, blinded to patients and treatments. In contrast
with the study by Berta et al., only stage 4 patients were
included in this study, resulting in shorter survival rates.
Our data analysis also showed a shorter survival associated
with apelin positivity, although the difference was only
marginally significant (P = 0.05). Most of the patients
without apelin positivity had an ECOG performance
status of 0 or 1 (P = 0.05). The two groups were also similar
in terms of demographic data, 6-month survival rate,
and 1-year survival rate. In line with previously reported
methods, patients with low (0 or 1 + apelin expression)
or high (2 + or 3 + apelin expression) apelin expression
were also compared, with no significant differences in all
parameters tested.
Two additional previous studies tested the prognostic
significance of apelin in other organ cancers. The first
of these studies involved patients with squamous cell
carcinoma of the oral cavity and a significant association
between high apelin positivity (3 +) and recurrence
rates (P = 0.038) was shown (20). In the second study,
apelin expression in the vascular endothelial cells was
demonstrated immunohistochemically in patients with
breast cancer, but no difference in apelin expression was
found between tumor and normal tissues (21).
The major limitations of our study include small
sample size and the retrospective nature of our analysis.
The principal factor responsible for our small sample size
was the inclusion of patients with an adequate amount
of biopsy samples both for immunohistochemistry and
apelin analysis, who also had to have adequate information
in their patient files regarding the stage of cancer, response
to chemotherapy, side effects, and prognosis.
In conclusion, our results do not suggest that apelin,
an angiogenic factor, may be used as a reliable prognostic
factor in this group of patients. Prospective studies with
larger sample size are warranted to better elucidate the
prognostic role of apelin in that condition.
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